Last-Hope drug offered to transplant patients with deadly blood clotting disorder
NCT ID NCT04247906
Summary
This program provides access to the investigational drug narsoplimab for patients who develop a serious blood vessel complication called HSCT-TMA after a stem cell transplant. It's for adults and children who have undergone transplant and developed this life-threatening condition when no other treatments are suitable. The goal is to control this dangerous complication in patients who may benefit based on their doctor's judgment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.